LRF’s MISSION
With a mission to eradicate lymphoma and serve those touched by this disease, the Lymphoma Research Foundation (LRF) is the nation’s largest lymphoma-focused health organization devoted to improving care through education and support services and improving outcomes through investment in the most promising lymphoma research.

Every 5 Minutes,
someone in the United States is diagnosed with some form of lymphoma and CLL.

$60 million
The Lymphoma Research Foundation has funded more than $60 million in lymphoma research, which has resulted in more than 370 grants to-date.

40,000
LRF funds more than 40,000 research hours each year for early-career scientists, enabling young investigators to maintain a research focus on lymphoma.
Dear Friends and Supporters,

At the Lymphoma Research Foundation (LRF), our mission to eradicate lymphoma and serve those touched by this disease drives every aspect of our work. While our mission is a bold one, we at LRF feel more equipped than ever to serve the more than one million people in the United States currently living with lymphoma/CLL.

As the lymphoma treatment landscape continues to evolve, LRF continues to support advancements in outcomes and care through service, education, support and investment in innovative research. We believe that today’s research will lead to tomorrow’s cures, and therefore remain steadfast in our dedication young investigators and more experienced leaders in the hematology-oncology space.

Last year, we saw tremendous advancements in lymphoma care, including the development of several novel agents and innovative therapies that have proven to increase survival rates and change the treatment landscape. We also continue to take great pride in the notion that LRF’s educational resources have helped patients and their loved ones become their own healthcare advocates, armed with the knowledge they need about these new developments so that they can make the most informed decisions based on their individual needs.

Thanks to the generosity of donors, volunteers, and partners we continue to find new ways to ensure that the lymphoma community can improve the future for all those affected by this blood cancer. Our goal must remain on progress for our community, to ensure that every lymphoma diagnosis is met with hope, care and the opportunity to thrive. We meet this challenge together, with confidence, compassion and care. Together, our community can make the biggest impact of all.
ONE COMMUNITY, ONE GOAL
ARMED WITH KNOWLEDGE, TOGETHER IN CARE
RESEARCH AND SCIENTIFIC HIGHLIGHTS

The Lymphoma Research Foundation’s Scientific Advisory Board (SAB) is comprised of 45 world-renowned lymphoma experts who guide all investment of LRF’s research portfolio. In 2019, LRF’s SAB welcomed a new Chair, Andrew D. Zelenetz, MD, PhD of Memorial Sloan Kettering Cancer Center. Dr. Zelenetz has been a member of LRF’s SAB since the Foundation’s inception, and is an active participant in LRF’s in-person Patient Education Programs, and has lent his scientific expertise to the development of LRF’s research portfolio, scientific workshops, educational materials and digital programming.

Dr. Zelenetz was joined by incoming Chair-Elect, Sonali Smith, MD of The University of Chicago, who will assume the role as Chair at the conclusion of Dr. Zelenetz’ term in 2021.

This SAB welcomed two new members in 2019, who bring expertise in research ranging from epidemiology to investigating new therapies for indolent lymphomas. Welcome James Cerhan, MD of Mayo Clinic, Rochester and Peter Martin, MD of Weill Cornell Medicine.

LRF Expands Scientific Meeting Portfolio
The Lymphoma Research Foundation’s research program supports innovative research in lymphoma not just through the Foundation’s grant portfolio, but through a robust calendar of scientific programs. These programs bring together researchers with a variety of expertise in lymphomas to share information and ideas, foster collaborations, and make recommendations on issues crucial to future research. In 2019, LRF expanded its scientific meeting offerings by hosting two inaugural workshops on Adolescent/Young Adult Lymphoma (AYA) and Marginal Zone Lymphoma.

LRF’s Adolescent/Young Adult Lymphoma Scientific Workshop marked the expansion of LRF’s AYA Lymphoma Initiative, Erase Lymphoma, founded in 2015 with support from the Paul Foundation. The 2019 AYA Scientific Workshop brought pediatric and adult oncologists and lymphoma researchers, regulatory officials, and industry representatives together for a two-day workshop examining the biological, clinical, epidemiological, and health services issues that cause unique complications in both caring for and conducting research on this patient population. Under the direction of AYA Lymphoma Steering Committee Co-Chairs Kara Kelly, MD of Oishei Children’s Hospital and Roswell Park Cancer Institute, and Thomas M. Habermann, MD of Mayo Clinic, Rochester, the workshop convened multi-industry experts to identify and address what is needed for adolescent and young adult lymphoma patients regarding research, education and advocacy.

To bring much-needed focus on marginal zone lymphoma (MZL), an extremely rare type of lymphoma, and to bridge the gap between North American and European researchers, LRF together with its program partner the International Extranodal Lymphoma Study Group (IELSG), hosted the first-ever U.S. based international scientific workshop on MZL. Co-chaired by LRF Scientific Advisory Board (SAB) members Morton Coleman, MD of Weill Cornell Medicine, and Thomas M. Habermann, MD of Mayo Clinic, the two-day workshop focused on current unmet needs in the field of MZL, with an emphasis on identifying opportunities for large-scale study designs that leverage the opportunities for collaboration that can be facilitated by LRF.
IN CONVERSATION WITH

ANDREW ZELENETZ, MD, PHD
LRF SCIENTIFIC ADVISORY BOARD CHAIR

You are a long-time member of the Lymphoma Research Foundation (LRF) Scientific Advisory Board (SAB). How did you first get involved with LRF?
I was involved with both parent organizations, the Cure for Lymphoma Foundation and the Lymphoma Research Foundation of America. After the organizations merged, I was asked to be a member of the LRF SAB and have been a continuous member since that time.

What do you hope to accomplish during your term as SAB Chair?
The LRF has been the premier organization for training young physicians and scientists to prepare them for a career in Lymphoma Research. One of the most successful programs has been the Lymphoma Clinical Research Mentoring Program (LCRMP) where fellows and junior faculty receive training and mentorship focused on clinical investigation. In addition to the on-site mentorship during the program, it helps these young investigators establish important contacts outside their home institution. I would like to see a similar program developed for laboratory and translational scientists, so that they may establish relationships and potentially collaborations with clinicians. We hope to pilot the program in 2021.

What notable updates have happened with the SAB in the past year?
Under the leadership of the immediate past SAB chair, Dr. Thomas Habermann, we conducted two important workshops. The first was focused on Marginal Zone Lymphoma and was a collaboration with the International Extranodal Lymphoma Study Group. This workshop brought together experts from all over the world for two-days of scientific discussions and identification of important areas where research needed to be focused. The second workshop focused on the Adolescent and Young Adult Lymphomas. This brought together both pediatric and adult oncologists who were meeting for the first time. This workshop contributed to the development of studies for this group of patients. I was honored to provide a briefing with Dr. Alvarnas of the City of Hope at the US Capital on the importance of CAR-T cell therapy for patients with lymphoma.

What are the most important things LRF and the SAB do to impact lymphoma research?
The LRF has had an important impact on a broad array of lymphoma re-
One of the important measures of success is how many grantees remain in the field of lymphoma research. A measure by which the LRF has been very successful. The SAB’s role is to help identify the most promising candidates who can make important contributions to the field and help advance our goal of improving outcomes and curing more patients. Furthermore, LRF has been able to provide larger grants to established investigators. The SAB has developed the Request for Proposals (RFP) to identify the areas of research that are ripe for progress and to review the research applications. In addition, the SAB has helped organize and run a series of focused workshops that have been able to bring investigators from around the world to advance the science and state of the art clinical.

Examples include the long-stand Mantle Cell Lymphoma Workshop as well as the inaugural Marginal Zone Lymphoma and Adolescent and Young Adult Lymphoma workshops in 2019.

You have been involved with LRF’s efforts to provide and advocate for funding for early career lymphoma researchers, including hosting the Biden Community Summit last September. Why is it important for LRF to continue to fund early career research?
This is largely addressed above. Young physicians and scientists trained in oncology can choose from a wide range of areas of study. It is important to the field of lymphoma that we attract the best and the brightest young investigators. Fellowship or post-doctoral training is key in the person’s ultimate career choice. The LRF is well known to oncology programs around the country to be a source of funding for lymphoma investigators thought the fellowship and career development programs. The adage of “follow the money” is not lost on fellows. We attract excellent proposals from across the country and have the opportunity to support the very best candidates most of whom choose careers in lymphoma research.

What recent developments in lymphoma give you the most hope for the future?
This is a golden age for lymphoma therapies. Novel cellular therapies such as CAR-T cell are in their infancy. I see a next generation of therapy that is likely to be more effective and potentially less toxic. Our greater molecular understanding of lymphoma-genesis and progression has led to the development of effective targeted therapies. Examples include inhibitors of Bruton’s tyrosine kinase, phosphoinositide 3-kinase and BCL2 to name a few. More targeted therapies are emerging, and combinations are proving to be highly effective. We are seeing molecular remissions in diseases such as chronic lymphocytic leukemia after short courses of combination therapy. Finally, we see the evolution of immunotherapy with new targets for immunotherapy was well as the introduction of checkpoint inhibitors that have proven to be highly active in Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. The goal is better treatments with fewer long-term side effects.

“The LRF has had an important impact on a broad array of lymphoma research. One of the important measures of success is how many grantees remain in the field of lymphoma research. A measure by which the LRF has been very successful.”

— Andrew Zelenetz, MD, PHD
What are the goals of the AYA Lymphoma Consortium?
LRF’s AYA Lymphoma Consortium strives to encourage increased collaboration between the pediatric and adult oncology fields to help bring attention to adolescent and young adults and improve the care that is delivered to them. The consortium was established as part of LRF’s AYA initiative, Erase Lymphoma.

LRF hosted its first-ever multi-stakeholder scientific workshop on AYA lymphoma. What were the main goals of this meeting and why was it important to convene a scientific meeting like this?
The goal of the meeting was to convene multi-industry experts—groups that rarely get the opportunity to work together—to bring new ideas forward and accelerate the pace of research. By keeping AYA’s in the forefront of lymphoma research, we can help ensure improvements in the future.

How does the AYA Lymphoma Consortium benefit patients?
Increased research and collaboration will continue to improve survival rates, and more importantly, maintain patient’s quality of life post-cancer. Increased collaboration between the pediatric and adult oncology fields will help to bring attention to adolescent and young adults and improve the care that is delivered to them.

Do you think the AYA Lymphoma Consortium will have an impact on lymphoma research?
The more we continue to have conversations about the needs of AYA’s, the better opportunity we have to raise awareness of this cohort and allow for innovations in research. By making individuals aware of the unique challenges that AYA’s face, we can shed a light on the importance to move research forward.

Why is a program devoted specifically to the AYA lymphoma cohort important?
While outcomes for the adult and pediatric cancer populations have improved over the years, there are still many gaps in improvements for AYA’s. This is due to a variety of unanswered questions about AYA’s including, understanding the biology of different cancers, age-appropriate care delivery, and adjusting outreach and care-plans for this demographic. We are still at the tip of the iceberg from a biological and research perspective and a greater emphasis and investment in AYA research will allow us to have a much broader understanding of both the disease as well as the psychological and social impact on patients.
Expansion of LRF’s Professional Education Program, Lymphoma Rounds
The Lymphoma Research Foundation’s professional education program, *Lymphoma Rounds*, provides a forum for healthcare professionals to meet on a regular basis and address issues specific to the diagnosis and treatment of their lymphoma patients. The Annual National *Lymphoma Rounds* meeting held in conjunction with the Lymphoma & Myeloma Congress, featured case presentations delivered by lymphoma experts across the country. The joint meeting benefited from collaboration and cross-promotion, allowed LRF to target new audiences, and helped the Foundation to further expand *Lymphoma Rounds* in New York City.

Living with Lymphoma Podcast
In 2019, LRF launched a podcast series entitled, *Living with Lymphoma*. The podcast is intended to help the lymphoma community better understand how to cope with the unique circumstances that a diagnosis of lymphoma presents. In its inaugural episodes, experts and patients discussed personal journeys and a range of psychosocial topics. Released in December, the inaugural episode, *Coping with Cancer During the Holidays*, featured post-lymphoma treatment recipient and LRF Ambassador, Dexter Neal along with Clinical Social Worker, Kristie Redfield of Memorial Sloan Kettering Cancer Center.

LRF Lymphoma Support Network
The Lymphoma Support Network (LSN) is a one-to-one peer support program for people with lymphoma and their caregivers. LSN connects patients and caregivers with volunteers who have had similar experiences. Volunteers are there to offer words of encouragement, and understanding, to help give others strength to meet the challenges they may have to face. In 2019, the Foundation had 205 new volunteer’s sign-ups for the Lymphoma Support Network. One of the highest increases in sign-ups since the program’s institution. Additionally, more caregivers than ever before expressed interest in joining the program. The growth of LSN will allow LRF to continue to serve the lymphoma community and provide peer-to-peer support to those in need.
What are the goals of the Lymphoma Rounds program?
The overall goal is to enhance the knowledge of lymphoma among the oncological community. It’s designed to educate everyone with an interest in oncology on the care of lymphoma patients.

How did the Lymphoma Rounds program expand in the past year?
We piloted the program in San Francisco in the hopes of expanding the program’s visibility on the west coast. This was an exciting moment for the Lymphoma Rounds program, and was received so well, that we have decided to make this a permanent location in the program series.

How have you seen the program evolve since its inception?
The program began in Chicago and has since expanded to several markets across the country. It is great to see how many healthcare professionals within the field of lymphoma are interested in the program and benefit from it. Also, in 2019 the Lymphoma Research Foundation began a partnership with the medical journal, Leukemia & Lymphoma, and the publication launched an LRF Lymphoma Rounds series. This section features selected case presentations from the Foundation’s live programs.

Why do you think Lymphoma Rounds is important for physicians?
It gives them an insight into the intricacies and challenges of diagnosing and treating lymphomas. We also choose to present particularly difficult or rare cases which allows an opportunity for participants to learn from each other and take that knowledge back to their own practices and patients.
Why did you decide to be a part of the Lymphoma Support Network?
LRF’s Lymphoma Support Network connected me with survivors who had gone through similar experiences. The words of encouragement, understanding and strength I received from my peers in this network were invaluable.

What is your favorite part of getting to interact with other patients/survivors?
I am able to help others and in turn, they certainly help me. It also gives me a sense of community and hope.

Why is it important to you to be able to give back to others going through a similar experience?
Cancer is a part of my life story and I am here to help others who may be struggling like I was whenever I can. These types of connections can be life-changing when you receive a lymphoma diagnosis, and I am so grateful to be able to give back to a community that gave me so much.

How have you evolved as a buddy over the years?
I have come full circle as a part of LRF’s Lymphoma Support Network. I started as someone seeking support during a time of great need, and now I get to be that buddy for others. I learn from each person I interact with and it makes me stronger as a survivor.

Why is the Lymphoma Support Network an important resource for patients and their loved ones?
It’s important to talk to people about one’s medical treatment and the psychosocial challenges that accompany that treatment. That is where LSN becomes so helpful. The less isolated you feel, the easier it is to get through treatments and know you are never alone.
ONE COMMUNITY, ONE GOAL
OUR COMMUNITY THRIVES TOGETHER
COMMUNITY IMPACT HIGHLIGHTS

Team LRF
Team LRF is the community fundraising program at the Lymphoma Research Foundation (LRF). A community of lymphoma survivors, caregivers, friends, family members, and supporters who raise awareness and critical funds to support those affected by this blood cancer. As part of Team LRF, individuals can participate in one of the Foundation’s signature events, including the Lymphoma Walks and the Lymphoma Research Ride, or Host or participate in, a unique fundraiser of their own. In 2019, LRF leveraged Facebook as a platform to raise funds for Team LRF Lymphoma Walks, the Lymphoma Research Ride or a do-it-yourself fundraiser easier than ever. Through integration with the Foundation’s peer-to-peer fundraising platform, supporters were able to connect their individual fundraising page with a Facebook Fundraiser in a few clicks.

Ticketed Events
The Lymphoma Research Foundation’s ticketed fundraising events, including the LRF Golf Invitation-al, Swirl: A Wine Tasting Series, and Annual Gala, are critical to raising funds to support LRF’s mission. Since 2013, the Foundation has been able to expand its Swirl: A Wine Tasting Series from its inaugural market in Miami to five additional markets including Chicago, Dallas, Minneapolis, New York City, and Orange County, Calif. In 2019, the Foundation marked a major milestone for the series, raising more than $1 million since the series’ inception and presented the 2019 Hope Award to the series founding sponsor, Southern Glazer’s Wine & Spirits (SGWS).

2019 Giving Tuesday Campaign
GivingTuesday, the Tuesday following Thanksgiving, Black Friday and Cyber Monday, is a campaign intended to create a national day of giving. In 2019, the Lymphoma Research Foundation focused its GivingTuesday campaign on empowering the lymphoma community to find their path to a cure. Through the collective power of giving the Foundation raised more than $58,000 on GivingTuesday—coupled with a matching gift from a generous donor, LRF raised a total of $73,000.
In what capacity do you give back to LRF through your Southern Glazer’s Wine & Spirits?

In 2013 we started a series of wine tasting events called Swirl. The Swirl series has taken place in many markets and continues in 2020. Since its inception the series has raised $1.2 million for LRF. SGWS also participates in the annual gala.

Why did SGWS feel it was important to give back to LRF?

The Chaplin and Glazer families, majority owners of SGWS, have built a culture of giving back to the communities they serve. The Swirl Series is a perfect event for SGWS to support as it educates the attendees about the great wines SGWS distributes while, of course, raising money and awareness for LRF.

How have you and your company/the company you work for, made an impact on LRF?

Certainly, we have made a financial impact and raised awareness of LRF. The interesting thing to me, however, is how many SGWS team members tell me how their family or friends have been touched by the disease and they are happy to be helping the fight to eradicate Lymphoma. Some have been there since the beginning of the program and continue to lend their support every year. The Swirl Series has become part of the fabric of SGWS giving back.

Why was the $1M mark for LRF’s Swirl series significant for SGWS?

The $1 million milestone coincided with SGWS receiving the Hope Award from LRF. I accepted the award on behalf of all the SGWS associates that made that achievement possible. Everybody was very proud of the achievement. Especially those that have been involved with the swirl event for a while.

How do you see your company’s relationship with the Foundation continuing/evolving in the future?

We are always looking to expand the series to other cities or tweaking the format. The host committees in each city do a great job and lead the execution in different cities. It would not be possible with local leaders like Leigh Olson, Michael Werner and Michelle and AJ Manas. We have interest in additional cites for 2021 such as New York and Philadelphia.
The Condensed Balance Sheets and Statements of Activities of the Lymphoma Research Foundation as of June 30, 2019 and 2018 have been derived from LRF’s audited financial statements. The Lymphoma Research Foundation’s complete set of audited financial statements and related information can be found on the Lymphoma Research Foundation’s website, lymphoma.org/annual report. The Financial Statements have been audited by KPMG LLP.
# Balance Sheets

**LYMPHOMA RESEARCH FOUNDATION**

**BALANCE SHEETS**

*in thousands* as of June 30, 2019

<table>
<thead>
<tr>
<th>Assets</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$1,560</td>
</tr>
<tr>
<td>Investments</td>
<td>13,452</td>
</tr>
<tr>
<td>Contributions and grants receivable</td>
<td>837</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>605</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$16,454</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Liabilities &amp; Net Assets</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Research grants payable</td>
<td>$2,997</td>
</tr>
<tr>
<td>Refundable advances</td>
<td>179</td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>451</td>
</tr>
<tr>
<td>Accrued salaries and vacation</td>
<td>157</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>3,784</strong></td>
</tr>
</tbody>
</table>

|                          |            |
| Unrestricted net assets   | 4,602      |
| Temporarily restricted net assets | 8,068   |
| **Total net assets**      | **12,670** |
| **Total liabilities and net assets** | **$16,454** |

# Condensed Statement of Activities

**LYMPHOMA RESEARCH FOUNDATION**

**CONDENSED STATEMENT OF ACTIVITIES**

*in thousands* as of June 30, 2019

<table>
<thead>
<tr>
<th>Unrestricted Contributions &amp; Revenues</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Special events revenues &amp; contributions</td>
<td>$7,538</td>
</tr>
<tr>
<td>Investment &amp; other income</td>
<td>376</td>
</tr>
<tr>
<td>Contributions &amp; revenues</td>
<td>7,914</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>4,099</td>
</tr>
<tr>
<td><strong>Total contributions &amp; revenues</strong></td>
<td><strong>$12,013</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Program services</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total expenses</strong></td>
<td><strong>$10,605</strong></td>
</tr>
<tr>
<td>Increase in unrestricted net assets</td>
<td></td>
</tr>
<tr>
<td>Increase in temporary restricted net assets</td>
<td>1,004</td>
</tr>
<tr>
<td><strong>Increase in net assets</strong></td>
<td><strong>$2,412</strong></td>
</tr>
</tbody>
</table>
SCIENTIFIC ADVISORY BOARD

THE LYMPHOMA RESEARCH FOUNDATION’S VOLUNTEER SCIENTIFIC ADVISORY BOARD, COMPRISED OF 45 WORLD-RENNOWNED LYMPHOMA EXPERTS, GUIDES THE FOUNDATION’S RESEARCH ACTIVITIES, SEEKING OUT THE MOST INNOVATIVE AND PROMISING LYMPHOMA RESEARCH PROJECTS FOR SUPPORT.

2019–2020 MEMBERSHIP

ANDREW D. ZELENETZ, MD, PhD
Chair
Memorial Sloan Kettering Cancer Center

SONALI M. SMITH, MD
Chair-Elect
The University of Chicago

RANJANA ADVANI, MD
Stanford University School of Medicine

ASH A. ALIZADEH, MD, PhD
Stanford University School of Medicine

STEPHEN ANSELL, MD, PhD
Mayo Clinic, Rochester

NANCY BARTLETT, MD
Washington University School of Medicine

KRISTIE A. BLUM, MD
Winship Cancer Institute of Emory University

CATHERINE BOLLARD, MD, MBChB
George Washington University
Children's National Medical Center

JAMES CERHAN, MD, PhD
Mayo Clinic, Rochester

ETHEL CESARMAN, MD, PhD
NewYork-Presbyterian Hospital
Weill Cornell Medicine

BRUCE D. CHESON, MD, FACP, FAAAS, FASCO
Past Chair, 2010–2012

MORTON COLEMAN, MD
Chair, Medical Affiliates Board
NewYork-Presbyterian Hospital
Weill Cornell Medicine

SANDEEP DAVE, MD, MS
Duke University

KIERON M. DUNLEAVY, MD
George Washington University
GW Cancer Center

KOJO S.J. ELENITOBA-JOHNSON, MD
University of Pennsylvania
Perelman School of Medicine

ANDREW M. EVENS, DO, MSc, FACP
Rutgers Cancer Institute of New Jersey

CHRISTOPHER R. FLOWERS, MD, MS
The University of Texas MD Anderson Cancer Center

JONATHAN W. FRIEDBERG, MD, MMSc
University of Rochester
James P. Wilmot Cancer Institute

LEO I. GORDON, MD, FACP
Past Chair, 2015–2017
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

THOMAS M. HABERMANN, MD
Immediate Past Chair, 2017–2019
Mayo Clinic, Rochester

STEVEN M. HORWITZ, MD
Memorial Sloan Kettering Cancer Center

ERIC D. HSI, MD
Cleveland Clinic

BRAD S. KAHL, MD
Washington University School of Medicine

KARA KELLY, MD
Roswell Park Comprehensive Cancer Center
University at Buffalo Jacobs School of Medicine

ANN S. LACASCE, MD
Harvard Medical School
Dana-Farber Cancer Institute

BRIAN K. LINK, MD
University of Iowa

IZIDORE S. LOSSOS, MD
University of Miami Health System
Sylvester Comprehensive Cancer Center

PETE MARTIN, MD
Weill Cornell Medicine

ARI MELNICK, MD
NewYork-Presbyterian Hospital
Weill Cornell Medicine

LINDSAY MORTON, PhD
National Cancer Institute

OWEN O’CONNOR, MD, PhD
Columbia University Medical Center

LAURA PASQUALUCCI, MD
Columbia University
H. Irving Comprehensive Cancer Center

BARBARA PRO, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

KANTI R. RAI, MD
Hofstra Northwell School of Medicine

KERRY J. SAVAGE, MD
British Columbia Cancer

Laurie Sehn, MD, MPH
British Columbia Cancer

MARGARET SHIPP, MD
Harvard Medical School
Dana-Farber Cancer Institute

EDUARDO M. SOTOMAYOR, MD
George Washington University
GW Cancer Center

CHRISTIAN STEIDL, MD
British Columbia Cancer

JOHN M. TIMMERMAN, MD
UCLA Jonsson Comprehensive Cancer Center

SVEN de VOS, MD, PhD
UCLA Jonsson Comprehensive Cancer Center

HANS-GUIDO WENDEL, MD
Memorial Sloan Kettering Cancer Center

MARGARET SHIPP, MD
Harvard Medical School
Dana-Farber Cancer Institute

MICHAEL E. WILLIAMS, MD, ScM
University of Virginia Cancer Center

FOUNDING CHAIR
JOSEPH R. BERTINO, MD
Rutgers Robert Wood Johnson Medical School
Rutgers Cancer Institute of New Jersey

2019 ANNUAL REPORT 13
BOARD OF DIRECTORS

2019–2020 MEMBERSHIP

MICHAEL WERNER
Chair
Chicago, IL

KEVIN FENNESSEY
Vice Chair
Naples, FL

DONNA REINBOLT
Vice Chair
Houston, TX

STEVEN J. PRINCE
Treasurer and Past Chair
Purchase, NY

LEIGH OLSON
Secretary
Miami Beach, FL

MICHAEL AKINYELE
Upper Marlboro, MD

ERIC COHEN
Chicago, IL

MORTON COLEMAN, MD
Chair, Medical Affiliates Board
New York, NY

TOM CONDON
Santa Barbara, CA

ERROL M. COOK
Past Chair
Boca Raton, FL

MICHAEL FROY
Chicago, IL

TOM GOLDSTONE
New York, NY

THOMAS M. HABERMANN, MD
Chair, Scientific Advisory Board
Rochester, MN

KEITH HOOGLAND
Glenvue, IL

JOHN LEONARD, MD
Past Chair, Scientific Advisory Board
New York, NY

BOB MCAULEY
Charlottesville, VA

KIM METCALF
Landenberg, PA

LANCE MEYEROWICH
New York, NY

JOHN A. NELSON
Westport, CT

STEVEN E. ROSEN
New York, NY

SHERI ROSENFELD
New York, NY

ROBERT WERNER
Aventura, FL

BRUCE YABLON
Chappaqua, NY

MEMBERS EMERITUS

JOSEPH R. BERTINO, MD
New Brunswick, NJ

BARBARA FREUNDLICH
Founder
New York, NY

JERRY FREUNDLICH
Founder and Past Chair
New York, NY
DONORS

LEADERSHIP CIRCLE

The Lymphoma Research Foundation recognizes the exceptional generosity of the members of the 2019 Leadership Circle. These individuals and foundations have provided hope to the lymphoma community through their commitment of supporting innovative research and reliable and compassionate services for everyone touched by this disease.

Mr. Michael Akinyele
Anonymous
Mr. and Mrs. Steven Aronow
The David R. and Patricia D. Atkinson Foundation
Ms. Maxa S. Berid, Esq.
Dr. Joseph R. Bertino
Mr. Jeffrey Block and Ms. Michele Gerus
Mrs. Elizabeth Brown
Dr. and Mrs. Bruce D. Cheson, MD
Eric and Stacey Cohen
Morton Coleman, MD
Condon Family Foundation
Gladys and Errol Cook
Jean and Steven Eichberg
Frank M. Ewing Foundation, Inc.
Kevin and Debra Fennessey
Mrs. Arlene Fischer
Norman J. and Doris Fisher Foundation
Barbara and Jerry Freundlich
Mr. Michael Froy
Mr. and Mrs. Thomas E. Goldstone & The Goldstone Fund
Dr. and Mrs. Thomas M. Habermann, MD
Mr. and Mrs. Keith A. Hoogland
Mr. Alex Kleyner

John P. Leonard, MD
Mr. and Mrs. Robert W. McAuley
Ms. Kimberly Metcalf
Mr. and Mrs. Eugene F. Murphy
John Nelson
Mr. and Mrs. Kenneth C. Newton
Leigh and Cory Olson
The Paul Foundation
David and Miriam Phalen and The Grinberg Family Foundation
Prince Family Foundation
Joey Ramone Foundation for Lymphoma Research
Donna and Paul Reinbolt
Mr. Steven E. Rosen
Lois and Jerry Rosenblum
Sheri and James Rosenfeld
Mr. and Mrs. Robert Sablowsky
Mr. Jeffrey Stedman
Florence and Robert Werner
Michael and Laura Werner
Mr. and Mrs. David C. Wiener
Mr. David Wintz
Andrea and Bruce Yablon
Dr. Adelaide W. Zabriskie
Andrew D. Zelenetz, MD, PhD

DONORS

DENISE AND LARRY MASON SOCIETY

The Denise and Larry Mason Society honors those who have chosen to support the Lymphoma Research Foundation with a bequest, creating a legacy of hope for the lymphoma community. The following bequests supported life-saving research and support for the lymphoma community in 2019.

The Carole M. Cohen Estate
The Estate of Pamela G. Lebowitz
The Estate of Denise Mason
The Jerome and Elaine Nerenberg Foundation
The Carl Olsen Revocable Trust
The Ruth and Samuel J. Rosenwasser Charitable Trust
The Estate of Sheila Tierman
DONORS

DISTINGUISHED EVENTS SUPPORTERS

LRF is grateful to the following donors that contributed to the success of the Foundation’s ticketed events throughout the 2019 calendar year.

GALA SPONSORS, TICKETS, JOURNAL ADS, DONATIONS

$100,000+
Anonymous
$75,000 - $99,999
Goldman Sachs Gives, at the request of R. Martin Chavez
The Connors Family
Friedman Family Foundation
Seattle Genetics, Inc.
Jerry Speyer and Katherine Farley
$50,000 - $74,999
Richard Friedman
Peggy and Al Kelly
Allison and Howard Lutnick
Amelia and Bayo Ogunlesi
Julian C. Salisbury
$25,000 - $49,999
Celgene Corporation
Crestview
Edward M. Matthews; The Starr Foundation
Susan and Ed Forst
Fried, Frank, Harris, Shriver & Jacobson LLP
Genentech
Kite Pharma, A Gilead Company
John A. Nelson
Daryl and Steven Roth
Stephen M. Scherr
Mr. David M. Solomon
Susan and Jeffrey Sussman
Merryl and James Tisch
Mr. John E. Waldron
$15,000 - $24,999
AbbVie, Inc.
Lisa and Alex Grinberg
Barrie and Glen Kassan

Jill and Thomas Marino
New York Presbyterian
Miriam and David Phalen
The Prince Family Foundation
Sheri and Jimmy Rosenfeld
Ellen Schoninger & Efraim Grinberg
Liselotte and Robin Vince
Weill Cornell Medicine
Florence and Robert Werner
Michael and Laura Werner

$10,000 - $14,999
Stacy Bash-Polley
Lisa and Richard Cashin
Celgene Corporation
The Condon Family Foundation
Gladys and Errol Cook
Peggy and Millard Drexler
Jill and Mark Fishman
Barbara and Jerry Freundlich
Mr. Justin Gmelich
Joan & Sanford I. Weill Department of Medicine
Kushner Companies Charitable Foundation
Stacey and Curtis Lane
The Lipsky-Karas family
Merck & Co., Inc.
Mr. and Mrs. David A. Messer
Mission Capital
Mr. Timothy J. O'Neill
Pfizer Inc.
Pharmacyclics Inc.
Ellen and James Riley
Stephanie and Steven E. Rosen
Lauren Rosenstock, Lisa and Rick Rosenstock, Marc Conney
Jane and Ned Sadaka
Gene Skyes
Laurence Stein
TG Therapeutics, Inc.
The Viniar Family Foundation
WB Wood
Brad Wechsler and Patty Newburger
Wells Fargo Securities

$5,000 - $9,999
Mr. Oded Aboodi
Mr. and Mrs. Michael Beaury
Mr. Alan M. Cohen
Timothy J. Curt and Dona Bissonette
The Ditzian Family
Debbie and Kevin Fennessey/Southern Glazers Wine & Spirits
Genentech
Mr. Dane E. Holmes
Sid and Ruth Lapidus
Leukemia & Lymphoma Society
Alla and Stan Liberman
Mr. and Mrs. Frank Linde
The Margaret & Daniel Loeb - Third Point Foundation
Mr. John R. Reinsberg
Alan Shuch and Leslie Himmel
Ms. Sarah E. Smith
Karin and David Strumwasser
Leah and Michael Weisberg
Mr. and Mrs. Richard Witten

$2,500 - $4,999
Linda and Ken Vaughn
Mr. and Mrs. John R. Barber
Mr. and Mrs. Michael Beaury
Mr. Steven Bloom
City National Bank
Dr. and Mrs. Martin E. Corwin
Gail and Larry Dobosh
Bennett and Emily Epstein
Mr. Peter R. Ezersky and Mrs. Janet B. Ezersky

$500 - $2,499
Anonymous
Iris and Nat Adler
Michael Alkineyele
Mr. David Angstrech
Mr. and Mrs. Eric A. Cohen
Mr. and Mrs. Lawrence J. Cohen
Mr. and Mrs. Eric A. Cohen
Mr. and Mrs. Harvey L. Cole
Morton Coleman, MD
Arlene Fischer/Danziger Foundation, Inc.
DTRM Biopharma
Mr. and Mrs. Stephen Roger Ehrlich
Mr. and Mrs. Edward Falkenberg
Dr. Robert M. Fischbein and Dr. Brenda M. Fischbein

The Fund for Blood Cancer & Cancer Research Inc.
Wendy Rosenthal Gellman
Roy and Gail Geronemus
Lori and Gary Gertzog
Mr. and Mrs. Sidney E. Goodfriend
Mr. and Mrs. Allen J. Grubman
Horacio and Patricia Gutiérrez
Mr. Forbes Hays
Mr. Lewis Kweit
John and Evelyn Lipori
Mr. and Mrs. Melvyn T. Masuda
Mr. and Mrs. Lance Meyerowich
Mrs. Paula Nelson
Beverly and Ed Robbins
Dr. Marcia and Dr. Perry Robbins-Wilf
Mr. Samuel S. Schneider
Mr. and Mrs. Benjamin Schneider
Mr. and Mrs. Jeffrey Spiegel
Verastem Oncology
Jeanette and Sherman Vogel
Andrea and Bruce Yablon

$500 - $2,499
Anonymous
Iris and Nat Adler
Michael Alkineyele
Mr. David Angstrech
Mr. and Mrs. Eric A. Cohen
Mr. and Mrs. Lawrence J. Cohen
Mr. and Mrs. Eric A. Cohen
Mr. and Mrs. Harvey L. Cole
Morton Coleman, MD
Arlene Fischer/Danziger Foundation, Inc.
DTRM Biopharma
Mr. and Mrs. Stephen Roger Ehrlich
Mr. and Mrs. Edward Falkenberg
Dr. Robert M. Fischbein and Dr. Brenda M. Fischbein

The Fund for Blood Cancer & Cancer Research Inc.
Wendy Rosenthal Gellman
Roy and Gail Geronemus
Lori and Gary Gertzog
Mr. and Mrs. Sidney E. Goodfriend
Mr. and Mrs. Allen J. Grubman
Horacio and Patricia Gutiérrez
Mr. Forbes Hays
Mr. Lewis Kweit
John and Evelyn Lipori
Mr. and Mrs. Melvyn T. Masuda
Mr. and Mrs. Lance Meyerowich
Mrs. Paula Nelson
Beverly and Ed Robbins
Dr. Marcia and Dr. Perry Robbins-Wilf
Mr. Samuel S. Schneider
Mr. and Mrs. Benjamin Schneider
Mr. and Mrs. Jeffrey Spiegel
Verastem Oncology
Jeanette and Sherman Vogel
Andrea and Bruce Yablon
DONORS

DISTINGUISHED EVENTS SUPPORTERS (CONTINUED)

Mr. and Mrs. George Gellert
Mr. and Mrs. Allen F. Goldman
Mr. and Mrs. Thomas E. Goldstone & The Goldstone Fund
Kenneth Goodman Family Foundation
Sarina Gwirtzman
Mr. and Mrs. David R. Haas
Mr. and Mrs. Stephen Hammerman
Michael Harwood
Philip Hidal
Mr. and Mrs. Gary D. Hirsch
The Honorable and Mrs. Harris N. Hollin
Ms. Tamara R. Igel
J.P. Morgan Chase Bank
Michael and Anna Kaye
The Kozaki Family
Mr. Edward Larmann
Mr. Morton Lembeck
Ms. Wendy Levine
Mr. Jack Levy
Gayle Lubnitzki
Mr. Stephen Maresco
Mr. and Mrs. Charles J. Marsden
Mr. William J. Milowitz
Helen Neuhaus
Mitchell Orfuss
Arnold S. Penner Foundation
Catherine and Leon Pollack
The Andrew and Lisa Rodman Foundation
Mr. Randy Rollner and Ms. Raine Heidenberg
John and Beth Rothschild
Mr. and Mrs. Michael Ruff
Scherzer International
Ms. Karen Seymour
Wagner Family Foundation Inc.
Mr. and Mrs. Earle Yaffa

GALA – RAISE IT FOR LRF

$100,000
John and Susan Hess

$75,000
The David Geffen Foundation

$50,000
Kenneth C. Griffin
Florence and Robert Werner
Michael and Laura Werner

$25,000
The Circle of Service Foundation
The Condon Family Foundation
The Connors Family
Mr. and Mrs. Keith A. Hoogland
The Paul Foundation
The Prince Family Foundation
Andrea and Bruce Yablon

$10,000
Shari Aronson
John A. Nelson
Stephanie and Steven E. Rosen

$5,000
Natan Bibliowicz
Jane and John Cafaly
Ellen Davis
Barrie and Glen Kassan
John Mara
Julia Morrow
Leigh and Cory Olson

$2,500
David and Miriam Phalen and The Grinberg Family Foundation
John Simkiss
Donald and Barbara Werner

$2,000
David and Peggy Tanner
Leah and John Leonard

$1,500
Dr. and Mrs. Thomas M. Habermann

$1,000
Mr. and Mrs. Michael Beaury
Ms. Alex Brannian
Barry Davis
Ms. Maralyn Ditzian
Gail and Larry Dobosh
Mr. and Mrs. David Freundlich
Mr. and Mrs. Alan Friedman
Lori and Gary Gertzog
Mr. and Mrs. Thomas E. Goldstone & The Goldstone Fund
John Goodwin
Michael Grace
Alex and Lisa Grinberg
Robert and Cynthia Hendrickson
Mr. C. Hugh Hindesley
Ms. Pamela Jones
Mark and Victoria Landau
Mr. Edward E. Matthews
David Nanus
Adam Nelson
Jennifer and Greg Passaretti
Mr. and Mrs. Thomas A. Potter
Amy and Richard Ruben
Efraim Grinberg and Ellen Schoninger
Mr. Bruce D. Wagner
Rebecca and Neal Weinstein
Dr. and Mrs. Vincent Zayas

$500
Michael Dinger
Ms. Laura Freundlich and Ms. Amy Babcock
Sam Horowitz and Eric Solomon
Drs. Jody and Steven Konstadt
Mr. and Mrs. Michael Mascarello
Mr. John Stoll

2019 ANNUAL REPORT
17
DONORS

DISTINGUISHED EVENTS SUPPORTERS (CONTINUED)

SWIRL SPONSORS AND DONORS

Connoisseur Sponsors ($2,500)
Conlon Commercial
Susan and Jon Diamond
Linda and Robert Finkel
Barbara and Jerry Freundlich
Mr. and Mrs. Mark Halpern
Chris Murphy of RSM US LLP
Diane and Paul C. Reily
Total Insurance Services, Inc.
The University of Chicago

Aficionado Sponsors ($1,000)
Robin and Thomas Armour
Frances and Edward Blair
BMO Harris Bank
Terry Brumfield
Joan and Vincent Carosella
Cynthia Chereskin
Linda Burns Coleman and Tony Dombrow
Joan Craig
Jeff Douthit
Dr. and Mrs. Melvin Drucker
Wende Fox Lawson
Full Monty Cycling Club
Green Family Foundation
Hilarie and Dusty Huscher
Mr. Michael Josephs
Robin Josephs and Patrick McGarvey
Allison and David Levin
Elizabeth and Michael Luttig
David Marks II
Kimberly Metcalf
Leigh and Cory Olson
Jill and Lee Pollock
Ms. Anna Rentz

Alan Salpeter and Shelley Gorson
Dr. and Mrs. Howard Schwartz
JoAnn Seagren and Scott Lang
Sam Skinner
Svoboda Capital Partners LLC
Wedner Family Foundation

Enthusiast Sponsors ($500)
Mr. Walter J. Andrews
Janice Barefoot and Nick Zocchi
Gladys and Errol Cook
Nancy Crane
Laurie and Steve Davis
Florida Funders
Melina and Gene Goldstein
Dr. and Mrs. Thomas M. Habermann
Dr. Andrew and Debbie Hirschl
Anne Hokin
Karyopharm Therapeutics
Leila K. Kight
Elizabeth and Michael Luttig
Rick Maehling
Magic City Casino
Mr. and Mrs. William Meyer
Ann O’Bradovich
PSD Solutions
Michele and Olivier Robert
Shahram Siddiqui
Marte V. Singerman
Simone and Zachary Stein
Robin and Mark Tebbe
Vanis Salon & Spa
Dr. Steven and Ana Weissman
Mr. and Mrs. Bruce D. Werner
Fred Zutel and Monique Vienes

ANNUAL LUNCHEON SPONSORS AND DONORS

Double Platinum Sponsor ($10,000)
Mr. and Mrs. Norton Sarnoff

Platinum Sponsor ($5,000)
Anonymous
Mrs. Joan G. Berman
Gladys and Errol Cook
Mrs. Jane C. Davis
Mrs. Billi W. Marcus
The Prince Family Foundation
Mr. and Mrs. Paul L. Schneider
Donald and Barbara Werner
Florence and Robert Werner

Gold Sponsor ($3,000)
Mr. and Mrs. Robert Britton
Ms. Joan H. Hauser

Silver Sponsor ($1,000)
Mr. and Mrs. Albert M. Anikstein
Ms. Helen Beck
Mr. and Mrs. Richard Behr
Judith Bronsteen
Mrs. Sondra S. Busch
Mr. and Mrs. Leon Cooperman
The Leon and Toby Cooperman Family Foundation
Mr. and Mrs. Igor Corneelsen
Mr. and Mrs. Robert H. Beber
Carol F. Hays
The Honorable and Mrs. Harris N. Hollin
Norman and Anne Jacobson
Mr. Marvin Goldstein and Mrs. Rhoda Malamut
Mr. and Mrs. Jules Reich
Marcia Robbins-Wilt, Ed.D
Ms. Marilyn Rush
Mr. and Mrs. Alvin Segal
Mr. and Mrs. Richard Shaw
DONORS

DISTINGUISHED EVENTS SUPPORTERS (CONTINUED)

Mrs. Nan Theodore
Jeanette and Sherman Vogel
Andrea and Robert Weiss

Bronze Sponsor ($1,000)
Charlotte Blumencranz
Leslie and Bernard Ettinger
Mr. and Mrs. Ivan Gefen
Lynne Halpern
Karen Herbstman
Mr. and Mrs. Ira S. Kent
Mr. and Mrs. Herman Lebersfeld
Sandra Lippy
Leigh and Cory Olson
Mitzi Oreman

Men In Black Sponsor ($1,000)
Barbara and Donald Golden

Men In Black Sponsor ($500)
Mr. and Mrs. Gerald Shapiro
Mr. and Mrs. Stephen F. Weinstein

Golf Invitational Sponsors
Co-Chairs ($50,000)
The Prince Family Foundation
Stern Family Philanthropic Foundation

Tournament Sponsor ($10,000)
Gantcher Family Foundation
Mr. Richard Kayne
Mr. and Mrs. David A. Messer
Mr. Steven E. Rosen

Foursome ($7,500)
Mr. and Mrs. William Apfelbaum
Mr. and Mrs. Robert Feilbogen
Mr. and Mrs. Gary D. Hirsch
Mr. Lawrence Kestin
Mr. Russell Kwiat
Mr. Thomas G. Mendell
Thomas G. and Andrea Mendell Foundation
Mr. Robert M. Rubin
Andrew Salzberg, MD
Mr. and Mrs. Mayo S. Stuntz, Jr.
Mr. Michael B. Targoff
Andrea and Bruce Yablon

Donations and Single Tickets ($5000)
Mr. Glenn August
Mr. and Mrs. Gary Davis
The Goodman-Lipman Family Foundation
Mr. and Mrs. Morris W. Offit

Donations and Single Tickets
($2,500 - $4,999)
Mr. and Mrs. Richard Feintuch
Elliot Horowitz & Company, LLP
JP Morgan Chase & CO
Mr. and Mrs. Ned Sherwood
Mr. Alexander Silver
Mr. Robert Horne
Mr. and Mrs. Barry Weisfeld

Donations and Single Tickets
($1,000 - $2,499)
Mr. Alfred Netter
Karen and Barry Wolf
William M. Doyle, Jr., Winston and Strawn LLP
Ms. Jacquelyn S. Henig
Mr. and Mrs. Michael Kramer
Karin and David Strumwasser
Mr. Edward Price
Mr. Stephen Chapin
Mr. William B. Finneran
Finneran Family Foundation
Mr. and Mrs. Jeffrey T. Golenbock
Mr. Irwin Levy
Mr. Steven Spiegel

Donations ($500 - $999)
Mr. Dale A. Adams
Mr. Marshall Cohen
Mr. Glenn E. Davis
Mr. and Mrs. Peter Schoenfeld
Mr. Robert Thornburn
DONORS

PEER-TO-PEER SUPPORTERS

LRF is grateful to the following fundraising teams that contributed to the success of the Foundation’s peer-to-peer fundraising events throughout the 2019 calendar year.

ARIZONA LYMPHOMA WALK
#InForLin
Beat It
BrewCrew for Connie
I ain’t Lymphin’ I’m Pimp’n’
Lance’s Team
Memory of Max Allen
Team Ed
Team Mayo Clinic Lymphomies
Team NXP
Tiro’s Heroes

HOUSTON LYMPHOMA WALK
#LymphomaWho? I don’t know her!
Chari’s Champs
Hodgkins Smogkings
MARISOL’S STARS
Mary’s Marauders
MD Anderson Cancer Center
Robert Half Technology
Toni’s Tribe
Tony Orta Crusaders
You’re the Cure!

CHICAGO LYMPHOMA WALK
#Support Team
CureFunders Team: Tanya, Kimberley, Rick & Diana
Hike for Mike 4.0
Jamaican a Difference
Laura’s Loony Lymphomettes
Nancy and Tony’s Cancer Fighting Ninjas
PwC LRF Team
STICKWALKERS
Team Papa
Team Sarnoff

MINNESOTA LYMPHOMA WALK
Kelly’s Krew
Mayo Clinic
Mr. K
Peggy’s Patrol
Pirates of the Cure-ibbean
Team - Live Long & Prosper
Team Deanna
Team Tim
The Knockouts
Tony’s Tigers

NEBRASKA LYMPHOMA WALK
“FAST” Fighters
Buffett Cancer Center Lymphomaniacs
Dream Weavers
Kicking Cancer Taking Names
Nebraska Medicine Pharmacy
’NoOneWalksAone’ #alexisstrong
Team Cara
Team Greco
Team Kueny
Union Pacific

NEW YORK LYMPHOMA WALK
BROOKLYMPHOMA J.C.
FUN-Raisers
Notorious C.U.R.E.
POPPY ALLAN
Survivor’s Obligation
Team AB
Team DESIMONE
Team Kweit
Team Vaughan
The Frank Footers

LYMPHOMA RESEARCH RIDE
Cheson Riders
Flaming Marmots
Lymphomaniacs
PCYC/JBI
S-2 [Survivors and Supporters]
Shaken Not Stirred
Team AbbVie
Team Assuncao
Team Celgene
LRF is grateful for the following companies that enhanced our mission by supporting our educational programs and support services. Thanks to their generous support, LRF was able to deliver free educational resources and support to the lymphoma community throughout the 2019 calendar year.

AbbVie, Inc.
Agios Pharmaceuticals, Inc.
Alexion Pharmaceuticals
Amgen Inc.
AstraZeneca
Atara Biotherapeutics
Bayer
Bristol-Myers Squibb
BTG International Inc.
Celgene Corporation
EUSA Pharma
Genentech
Genzyme Corporation
Gilead Sciences, Inc.
Helsinn Therapeutics, Inc.
Incyte Corporation
Janssen Biotech, Inc.
Jazz Pharmaceuticals
Kite Pharma, A Gilead Company
Kyowa Kirin, Inc.
Mallinckrodt Pharmaceuticals
MEI Pharma, Inc.
Merck & Co., Inc.
Novartis Pharmaceuticals Corporation
Pfizer, Inc
Pharmacyclics, Inc.
Rigel Pharmaceuticals, Inc.
Sandoz Inc.
Seattle Genetics, Inc.
Spectrum Pharmaceuticals, Inc.
Stemline Therapeutics
TG Therapeutics, Inc.
Verastem Oncology

LRF is grateful to the following donors that help to fund innovative investigators that have the greatest potential to impact research, and convene renowned scientific meetings which set research and care agendas for all those caring for lymphoma patients, throughout the 2019 calendar year. Sponsors of LRF Grants have no input into the selection of the grantees or their research projects.

CLINICAL INVESTIGATOR CAREER DEVELOPMENT AWARD
Genentech

POSTDOCTORAL FELLOWSHIP GRANT
AstraZeneca
Bristol-Myers Squibb
Pfizer, Inc.

ADOLESCENT/ YOUNG ADULT SCIENTIFIC WORKSHOP
The Paul Foundation (Initiative Founding Sponsor)
Bristol-Myers Squibb
Foundation Medicine
Kite Pharma, A Gilead Company
Seattle Genetics

MARGINAL ZONE SCIENTIFIC WORKSHOP
AstraZeneca
BeiGene
Celgene Corporation
Genentech
Kite Pharma, A Gilead Company
Pharmacyclics, Inc.
Verastem Oncology